Dopamine D2 Receptor-Mediated Regulation of Pancreatic β Cell Mass

Daisuke Sakano,1 Sungik Choi,2 Masateru Kataoka,2 Nobuaki Shiraki,1 Motonari Uesugi,3 Kazuhiko Kume,4 and Shoen Kume1,*

1Department of Life Science and Technology, School of Life Science and Technology, Tokyo Institute of Technology, 4259-B-25 Nagatsuta, Midori-ku, Yokohama, Kanagawa 226-8501, Japan
2Division of Stem Cell Biology, Institute of Molecular Embryology and Genetics, Kumamoto University, Honjo 2-2-1, Kumamoto 860-0811, Japan
3Department of Chemical Biology, Institute for Chemical Research, Institute for Integrated Cell-Material Sciences, Kyoto University, Uji, Kyoto 611-0011, Japan
4Department of Neuropharmacology, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe Street, Mizuho, Nagoya 467-8603, Japan

*Correspondence: skume@bio.titech.ac.jp
http://dx.doi.org/10.1016/j.stemcr.2016.05.015

SUMMARY

Understanding the molecular mechanisms that regulate β cell mass and proliferation is important for the treatment of diabetes. Here, we identified domperidone (DPD), a dopamine D2 receptor (DRD2) antagonist that enhances β cell mass. Over time, islet β cell loss occurs in dissociation cultures, and this was inhibited by DPD. DPD increased proliferation and decreased apoptosis of β cells through increasing intracellular cAMP. DPD prevented β cell dedifferentiation, which together highly contributed to the increased β cell mass. DRD2 knockdown phenocopied the effects of domperidone and increased the number of β cells. Dnd2 overexpression sensitized the dopamine responsiveness of β cells and increased apoptosis. Further analysis revealed that the adenosine agonist 5′-N-ethylcarboxamidoadenosine, a previously identified promoter of β cell proliferation, acted with DPD to increase the number of β cells. In humans, dopamine also modulates β cell mass through DRD2 and exerts an inhibitory effect on adenosine signaling.

INTRODUCTION

Diabetes is a progressive disorder characterized by elevated blood glucose levels, which causes organ complications. Both type 1 and late-stage type 2 diabetes lead to depletion of pancreatic islet β cells. Islet transplantation is a promising therapy to improve glycemic control. However, organ shortages and the loss of islet cells shortly after transplantation are major obstacles. Advances have been made in the generation of mature pancreatic β cells from pluripotent stem cells to overcome these problems. However, a thorough understanding of β cell mass regulation is required.

β Cells have been reported to have the potential to proliferate after experimental ablation, such as chemical treatment or partial pancreatectomy (Bonner-Weir et al., 2010) (Cano et al., 2008; Nir et al., 2007; Xu et al., 2008). Although controversial, β cells have also been reported to be generated from other cell sources, such as pancreatic ducts (Finegood et al., 1999; Sharma et al., 1999; Xu et al., 2008) and endogenous progenitor or trans-differentiated α, δ, or acinar cells, under specific conditions that lead to a nearly complete loss of β cells (Baeyens et al., 2005; Collombat et al., 2009; De Breuck et al., 2003, 2006; Xu et al., 2008). During regeneration, simple self-replication of β cells has been shown to be the primary source of new β cells (Dor et al., 2004; Kataoka et al., 2013). However, the mechanisms that regulate β cell proliferation are not well understood. Glucose has been identified as a signal that controls β cell proliferation through glucokinase activation and subsequent downregulation of cyclin D2 expression (Porat et al., 2011; Salpeter et al., 2011). In addition, several molecules, such as adenosine kinase inhibitors and glucagon-like peptide-1 (GLP-1), have been shown to promote β cell proliferation (Andersson et al., 2012; Berneal-Mizrachi et al., 2014). Moreover, dedifferentiation has also been shown to be a mechanism that triggers β cell loss (Talchai et al., 2012). Many studies have been aimed at identifying molecules that enhance β cell proliferation, which could restore proper β cell function and ultimately cure type 1 and type 2 diabetes. Recently, in a screening of a pharmacologically bioactive small-molecular-compound library, we identified molecules that enhance the differentiation of mouse embryonic stem cells (ESCs) into pancreatic β cells. We extended our study and established a primary islet culture system for screening small chemical compounds that enhance β cell proliferation. Here, we identified domperidone (DPD), a dopamine D2 receptor (DRD2) antagonist, as a potent enhancer of β cell proliferation and investigated the underlying molecular mechanism.

RESULTS

A Screening System for Chemicals that Promote β Cell Proliferation

To screen for chemicals that promote β cell proliferation, we established an islet dissociation culture system, in
which islets were dissociated into single cells and plated onto gelatin-coated 384-well plates.

In our islet dissociation culture, endocrine cell types were obtained at a proportion that reflected normal islet composition, i.e., approximately 80% insulin-positive (Ins+) cells, 20% glucagon (Gcg)+ cells, 5% somatostatin (Sst)+ cells, and 1% pancreatic polypeptide (PP)+ cells (Figures 1B–1F, day 1). Other cell types, such as vimentin (Vim)+ mesenchyme cells, amylase (Amy)+ exocrine cells, and others, were also observed (Figure 1F). In the culture, the cells appeared to gradually become apoptotic, and the number of islet cells decreased with time.

To determine the assay conditions, we first tested the period of 5-ethynyl-2'-deoxyuridine (EdU) exposure of the dissociated islets. EdU incorporation in Ins+ cells increased for up to 72 hr of exposure to EdU (Figure S1A). EdU incorporation in Ins+ cells was observed at a substantial level on days 1–3 or days 3–5, and significantly decreased on days 5–7 after islet dissociation (Figure S1B). Therefore in our initial screen, the 48-hr EdU exposure was adopted and chemicals were added to the cultures beginning on days 3–5, and the numbers of total cells and Ins+ cells were counted and EdU positivity in Ins+ cells determined on day 5.

**Domperidone, a DRD2 Antagonist, Promotes β Cell Proliferation**

We tested a library of 1,120 biologically active compounds arrayed as single compounds in DMSO. Candidate compounds that increased the numbers of total cells and Ins+ cells were selected as primary hits. Of our hit compounds, a DRD2 antagonist, DPD, showed the strongest effect.

DPD is known to be a specific antagonist of DRD2, which is a G-protein-coupled receptor (GPCR). DRD2 is known to mediate Gz1 signaling, which inhibits adenylate cyclase and decreases cyclic AMP (cAMP) upon dopamine binding. Addition of DPD increased the number of EdU+ proliferative Ins+ β cells (Figures 2A–2B) in the culture on day 5. DPD specifically increased the proportion of EdU+ cells among the Ins+ cells (Figure 2C), resulting in a specific increase in Ins+ cells but not other cell types (Figure 2D). Time-dependent application of DPD revealed that early application of DPD from day 1 or day 3 increased β cell

Figure 1. A Screening System for Chemicals that Promote β Cell Proliferation
A high-throughput screening system was established to identify chemicals that promote β cell proliferation. (A) Schematic drawing of the screening system. Dissociated islet cells were plated in a gelatin-coated 384-well plate at 2,000 cells/plate and cultured for 5 days, treated with EdU or test chemicals on days 3–5, and assayed on day 5. (B–E) Immunocytochemistry analysis of the islet culture on day 1 (B, C, D) or day 5 (E). (F) Total number of cells per well, showing the number of endocrine cells (PP+, Sst+, Gcg+, Ins+), exocrine cells (Amy+), and mesenchymal cells (Vim+) in the culture on day 1 (d1), d3, and d5 (mean ± SD, three independent experiments, each with four replicates).
number effectively, but late application (on day 5) produced minimal effects (Figure S2).

Over time, the islet cells in our culture assays formed clusters, stopped proliferating, and became caspase-3/7-positive (cell event-positive) apoptotic cells, which led to a decrease in cell number. We then assessed whether DPD could prevent β cell apoptosis. As expected, in the presence of DPD, apoptosis was significantly reduced (Figures 2E–2G). Taken together, our results showed that DPD increased cell proliferation and decreased apoptosis of Ins+ cells by antagonizing the action of dopamine through DRD2.

To determine whether dopamine acts as an upstream signaling molecule that modulates β cell proliferation and cell death, we tested the effects of dopamine and cAMP on proliferation and apoptosis. The results showed that dopamine decreased the number of Ins+ cells, which was reversed by the addition of DPD. In contrast, the addition of a cell-permeable cAMP analog, dibutyryl cAMP (dBu-cAMP) increased the number of Ins+ cells; however, this was not affected by the addition of dopamine, indicating that cAMP is likely downstream of dopamine. These results suggested that dopamine functions to negatively regulate β cell proliferation and promote cell death by decreasing cAMP levels through DRD2 (Figure 2H).

**DPD Treatment Protects β Cells from Dedifferentiation and Increases β Cell Mass**

In our islet dissociation culture, we observed an increase in the proportion of “other” cells that were not stained with the antibodies tested. DPD treatment resulted in an increase in Ins+ cells and simultaneous decrease in “other” cells (Figure 2D). The results thus urged us to hypothesize that β cell dedifferentiation occurs, so that “other” cells...
that represent dedifferentiated β cells increase, and that DPD might protect β cells from dedifferentiation. To test this possibility, we used islets harvested from mice bearing both Ins2-Cre (RIP-Cre) and Rosa26-loxP-Stop-loxP-EYFP transgenes, in which β cells that once expressed insulin would be labeled permanently with EYFP (Figure 3A). If β cell dedifferentiation occurs during dissociation culture, the EYFP-labeled Ins+ β cells would turn into Ins-negative (Ins−) cells. As a result, we found that dedifferentiation of β cells actually occurred. On day 3 after dissociation, many EYFP+/Ins+ cells were observed. By contrast, on day 5, the ratio of EYFP+/Ins+ cells decreased and EYFP+/Ins− cells increased. DPD addition rescued the reduction of EYFP+/Ins+ cells and prevented the increase of Ins−/EYFP dedifferentiated cells, whereas dopamine addition accelerated the reduction of EYFP+/Ins+ cells (Figure 3B).

We further assayed for EdU incorporation and apoptosis. Our results revealed that proliferation was observed in EYFP+/Ins+ β cells, but not in the dedifferentiated EYFP+/Ins− cells (Figures 3C–3E). EdU incorporation revealed that DPD promoted proliferation of the differentiated β cells (Ins+/EYFP+ cells), but not the dedifferentiated β cells (Ins−/EYFP− cells). Dopamine decreased proliferation of the Ins+/EYFP+ β cells (Figure 3F). Caspase-3/7 staining revealed that apoptosis was detected mainly in the Ins+/EYFP+ β cells but not in the dedifferentiated Ins−/EYFP+ β cells. DPD protected and dopamine increased apoptosis of the Ins+/EYFP+ β cells (Figures 3G–3I, 3J). The dedifferentiated β cells showed low adherence properties and tended to detach from plates; therefore, their cell numbers might be underestimated (Figure 2D, “other” cells and Figure 3, green bars).

Taken together, our results revealed that β cell dedifferentiation is the major mechanism for β cell loss that occurs during islet dissociation culture, which is mediated through dopamine signaling. Inhibition of dopamine signal increased β cell number mainly through the maintenance of the differentiated state of β cells, although its effects on decreasing apoptosis and increasing proliferation of β cells also account for the increased β cell mass.

Loss-of-Function and Gain-of-Function Studies of the Role of Dopamine-DRD2 Signaling in Regulating Cell Number and Apoptosis in MIN6 Cells

To examine the function of dopamine signaling in detail we used MIN6 cells, a β cell line. The number of MIN6 cells increased in cultures treated with DPD or dBu-cAMP. By contrast, dopamine treatment decreased the number of MIN6 cells (Figure 4A). DPD treatment increased proliferation assayed by EdU incorporation (Figure 4B). These results in MIN6 cells phenocopied those observed in our primary islet culture. We then assayed intracellular cAMP levels after various chemical treatments. DPD increased cAMP levels whereas dopamine decreased cAMP levels. When DPD was added together with dopamine, the dopamine-mediated decrease in cAMP was reversed (Figure 4C). Taken together, our results strongly suggest that MIN6 proliferation is mediated by cAMP signaling and that dopamine activates DRD2, decreases intracellular cAMP levels, and reduces the number of MIN6 cells.

We then established a Dnl2-knockdown (D2KD) MIN6 cell line by introducing a D2shRNA-mRFP construct, in which D2shRNA expression could be monitored as mRFP expression (Figure 4D). The D2KD MIN6 cell lines showed that Dnl2 expression was approximately 40% that of the wild-type MIN6 cells (Figure 4E). Cell number was significantly increased in D2KD MIN6 cells, to a level similar to that of the DPD-treated controlvector-introduced non-silencing (NS) cells (Figure 4F). DPD treatment did not further increase the number of D2KD MIN6 cells. However, due to the partial knockdown of Dnl2 in D2KD MIN6 cells, dopamine treatment still inhibited cell proliferation, but to a lesser degree than that in the vector-transfected control MIN6 cells (Figure 4F, NS). The addition of dBu-cAMP to the D2KD MIN6 cells did not further increase cell numbers, suggesting that in D2KD MIN6 cells, cAMP mediates the increase in cell number. Taken together, the results show that in MIN6 cells, treatment with DPD increased cell numbers by antagonizing dopamine signaling through DRD2, and that dopamine negatively regulates cell proliferation by

Figure 3. DPD Protects Pancreatic β Cells from Dedifferentiation and Thus Enhances Proliferation and Decreases Apoptosis during In Vitro Dissociation Culture

The effects of DPD and dopamine (DA) in dedifferentiating β cells. (A) R26-EYFP homozygote (+/+) and RIP-Cre homozygote (+/+) mouse were crossed and RIP-Cre(+/−)/R26-EYFP(+/−) mice were generated. (B) The dissociated islet cells were cultured, and applied with different chemicals on days 3–5. Dedifferentiated β (Ins+/EYFP+) cells were observed in control (DMSO)-, DPD-, or dopamine-containing culture conditions, assayed on day 5. DPD treatment reduced Ins+/EYFP+ dedifferentiated cells. (C–F) DPD treatment (days 3–5) (C–E) increased EdU (labeled on days 3–5) incorporation in Ins+/EYFP+ cells (golden bars), but not in dedifferentiated cells (Ins−/EYFP+, green bars). (G–J) DPD treatment (days 3–5) (G–I) reduced caspase-3/7+ cells in Ins+/EYFP+ cells (golden bars). Data represent mean ± SD. All data are obtained from three to four independent experiments, each with three to four replicates. *p < 0.01, *p < 0.05, Student’s t test. Scale bar represents 50 µm.
Figure 4. Loss-of-Function and Gain-of-Function Studies of the Dopamine D2 Receptor DRD2 in MIN6 Cells

The effects of DPD and dopamine (DA) in control (A, B, C, G) and Drd2-knockdown (D, E, F) or Drd2-overexpressing (H, I) MIN6 cells. (A) The number of MIN6 cells per well after 4 days of chemical treatment (days 3–7). Dopamine treatment decreased the number of cells, whereas DPD or cAMP treatment increased the number of MIN6 cells (five independent experiments, each with three to six replicates). (B) DPD increased proliferation of MIN6 cells revealed by EdU incorporation (48 hr) assay (four independent experiments, each with four replicates). (C) Relative cAMP levels after 6 hr of chemical treatment on day 3. DPD increased intracellular cAMP levels, whereas dopamine decreased intracellular cAMP levels, and DPD reversed the dopamine-mediated decrease. (D–F) Drd2 knockdown increased cAMP levels and phenocopied DPD effects. (D) Upper panel: a schematic of the lentiviral vector used for Drd2 shRNA-mRFP expression. Lower panel: fluorescence and transmission images of the Drd2-knockdown MIN6 cells (D2KD). (E) D2KD (legend continued on next page)
Dopamine Modulates β Cell Proliferation by Acting as an Inhibitory Signal for Adenosine

The adenosine signaling pathway has been reported to be a potent signal for β cell regeneration (Andersson et al., 2012). The adenosine agonist 5′-N-ethylcarboxamidoadenosine (NECA), which acts through the adenosine receptor A2a (ADORA2A), was reported to increase β cell proliferation. ADORA2A is a GPCR that is known to mediate Gαi signaling to activate adenylyl cyclase and increase intracellular cAMP. ADORA2A and DRD2 have been reported to be highly co-localized and to form heterodimers (Canals et al., 2003).

To gain insight into the relationship between adenosine signaling and dopamine function in terms of β cell proliferation, we examined the possible interaction between ADORA2A and DRD2. Duolink in situ proximity ligation assays revealed that DRD2 and ADORA2A are expressed and form a heterodimer in dissociated mouse pancreatic β cells (Figures 5A–A”). The interaction of DRD2 and ADORA2A was further confirmed by co-immunoprecipitation with antibodies against ADORA2A and DRD2 (Figure 5B). DRD2-ADORA2A heterodimer formation was enhanced by dopamine but suppressed by DPD or NECA addition (Figures 5C–5G). The results suggest an inhibitory effect of heterodimer formation against adenosine signaling.

We then tested islet β cells using our primary culture system (Figures 5H–5J). NECA alone increased the number of β cells and reversed the negative effects of dopamine, similar to the dopamine-inhibitory effect of DPD. NECA was shown to increase EdU incorporation (proliferation) of β cells and decrease apoptosis. Similar to DPD, NECA effectively rescued the proliferation of dopamine-treated β cells. However, NECA seemed to be less effective than DPD for rescuing dopamine-triggered apoptosis (Figure 5; p = 0.06).

We also tested the effect of NECA in MIN6 cells (Figure 5A). Treatment with NECA or DPD alone increased the number of MIN6 cells when present at ≥1.0 μM (D.S. et al., unpublished data). At lower concentrations, DPD and NECA work together to yield even more numbers of MIN6 cells. Under Drd2 knocked-down background, NECA was more effective in increasing cell number compared with control wild-type MIN6 cells (Figure 5B). These results suggest that a basal dopamine signal might exert negative effects on ADORA2A-mediated β cell proliferation.

Taken together, our results suggest that dopamine-DRD2 signaling negatively regulates proliferation and increases apoptosis, through inhibition of adenosine-ADORA2A signaling that positively regulates proliferation and reduces apoptosis. DRD2 and ADORA2A form homo- or heterodimer. We hypothesize that binding of dopamine to DRD2 promotes DRD2-ADORA2A heterodimer formation, through which dopamine negatively regulates adenosine-ADORA2A signaling, and vice versa (figure 5K). Integration of these two signals is important for the regulation of β cell proliferation.

**cells showed a partial decrease in Drd2 expression (two independent experiments, each with three replicates). (F) Responses of D2KD cells to dopamine chemicals. DPD increased cell number for 9 days culture, but not in D2KD cells. The effect of dopamine decreased in knockdown cells (four independent experiments, each with four replicates). (G–I) Dopamine treatment of wild-type (G) or Drd2-overexpressing (I) MIN6 cells on days 3–7. Dopamine dose-dependently increased the number of apoptotic cells (G) (three independent experiments, each with four replicates). Upper panel in (H) shows a schematic of the FLAG-tagged Drd2-expressing vector, and lower panel shows RT-PCR analysis of the exogenously overexpressed Drd2 in MIN6 cells. MIN6 cells overexpressing Drd2 (D2-OE) showed increased sensitivity to dopamine. Up to 37% of the cells became apoptotic after treatment with 10 μM dopamine (I) (three independent experiments, each with three replicates). **p < 0.01, *p < 0.05 compared with control DMSO-treated cells. Data represent mean ± SD. Student’s t test. Scale bar, 100 μm.**
mass, and the differentiation versus dedifferentiation states of β cells.

**DPD Is Also Effective in Human β Cells**

We then tested the effects of DPD to examine whether a similar mechanism could be applied to human islet β cells. Human β cells from a single donor were dissociated and subjected to assays for EdU incorporation and apoptosis. With human islets, chemical treatments were done on days 1–3 and assayed on day 3. We found that treatment with DPD, dopamine + NECA, dBu-cAMP, or SIT (iodotubercidin), an adenosine kinase inhibitor, increased the expression level of an anti-apoptotic protein BCL2 (Figure 6A). Although NECA alone did not induce BCL2 expression in the human β cells, it induced Bcl2 in the mouse β cells (D.S., unpublished data). Expression of a pro-apoptotic protein, BAX, was increased with dopamine treatment (Figure 6B). DPD, NECA, DPD + NECA, dBu-cAMP, or SIT increased total Ins+ cell numbers and EdU (24 hr) incorporation and reduced apoptosis, whereas dopamine decreased total Ins+ cell number and EdU incorporation and increased apoptosis (Figures 6C–6E). Our results suggest that a similar mechanism exists in human islet β cells and that dopamine acts as a negative regulator for β cell mass. Dopamine inhibits proliferation and triggers apoptosis, and inhibition of dopamine signal reduces apoptosis and increases β cell number.

**DISCUSSION**

Here, we utilized an adult islet dissociation culture system to identify chemicals that promote β cell proliferation. We revealed that in islet cell dissociation culture, β cell proliferation was triggered and at the same time β cell loss due to apoptosis and dedifferentiation of β cells was observed. Therefore, our islet cell dissociation culture system might represent a state seen in type 1 or type 2 diabetes, where disruption of cell-cell communication between islet cells promotes β cells to trigger failures in maintaining their identities and undergo apoptosis. Utilizing this assay system, we identified DPD, an antagonist of DRD2 signaling, as a chemical that specifically increased β cell mass by antagonizing dopamine signaling. Dedifferentiation of β cells seems to contribute to the major part of β cell loss in our present islet dissociation culture. Dopamine signaling, which is mediated by DRD2, decreases cAMP and triggers dedifferentiation and apoptosis of β cells. Antagonizing dopamine signaling by adding DPD protected β cells from dedifferentiation, apoptosis, and increased proliferation.

In MIN6 cells, Drd2 knockdown increased cell number. Therefore, dopamine might function as an autocrine inhibitor produced from β cells themselves. Activation of dopamine signaling through DRD2 seems to be a default state for β cells to inhibit proliferation, so that removal of the dopamine signal might be necessary for re-entry into the cell cycle. Dopamine has been reported to modulate proliferation and apoptosis of Ins+ cells (Garcia Barrado et al., 2015; Garcia-Tornadu et al., 2010). These previous reports and our present results provide strong evidence for the importance of dopamine signaling in regulating β cell mass. MIN6 cells treated with DPD showed higher cAMP levels, suggesting that DPD enhanced proliferation by regulating cAMP. Importantly, we further revealed that DPD also increased Ins+ cell number and proliferation, and decreased apoptosis in human islet β cells. Therefore, the mechanism found in mice also functions in humans.

There are five different dopamine receptor subtypes, one of which, DRD2, is expressed in pancreatic β cells of
humans and rodents (Rubi et al., 2005; Ustione and Piston, 2012). In the pancreas, dopamine is reported to function through the DRD2 receptor as an inhibitory signal against insulin secretion. In β cells, dopamine is synthesized from circulating L-Dopa, which is produced by the gastrointestinal tract (Ustione et al., 2013). Knockdown of DRD2 in INS-1 cells (a β cell line) resulted in increased insulin secretion (Wu et al., 2008). However, global Drd2-knockout mice showed impaired insulin secretion, which caused glucose intolerance (Garcia-Tornadu et al., 2010). Since dopamine is reported to regulate insulin secretion, we then tested whether insulin affects β cell proliferation or cell death in our culture, and found that insulin at high concentration (>100 nM) inhibited β cell proliferation regardless of DPD (Figure S5A). Insulin also promoted apoptosis at low concentrations, which was not rescued by DPD treatment.

Figure 6. DPD and NECA Promoted Proliferation and Suppressed Cell Death in Human β Cells

(A and B) The effects of dopamine (DA) and adenosine signaling were tested in human primary culture by treating human islet cells with chemicals on days 1–3, and assayed on day 3. DPD, NECA, dBu-cAMP, and 5′-iodotubericidin (5IT), an inhibitor of adenosine kinase, increased the expression level of BCL2 (A), whereas dopamine increased the expression of BAX (B) in human islet cells. (C) Total cell number per well, showing the number of Ins+ cells increased by adding DPD, NECA, DPD + NECA, cAMP, or 5IT. (D) EdU incorporation assayed for 24 hr. DPD, NECA, cAMP, and 5IT increased EdU incorporation whereas dopamine decreased EdU incorporation in human β cells. (E) Dopamine promoted apoptosis, whereas DPD, NECA, cAMP, and 5IT decreased apoptosis. Data represent mean ± SD. Data are from a single donor and each point represents three replicates. **p < 0.01, *p < 0.05 compared with control (open bars), Student’s t test.
(Figure S5B). We interpret the seemingly contradictory previous reports and our results to mean that the insulin signal is toxic for β cells and that the inhibitory dopamine signal against insulin secretion might be important for protecting β cells from a high workload. The inhibitory effects of the dopamine signal on β cell proliferation might also function as a brake. Determining how the dopamine signal is regulated is important for understanding its action.

Recently, we found that vesicular monoamine transporter 2 (VMAT2) regulates monoamine (including dopamine) storage by acting as a negative regulator, such that high monoamine levels inhibit the progression from Pdx1+ pancreatic progenitor cells to Neurog3+ endocrine progenitor cells of ESC-derived pancreatic progenitor cells and during embryonic pancreatic development (Sakano et al., 2014). VMAT2, which regulates dopamine storage, and tyrosine hydroxylase, which synthesizes dopamine, are expressed in both the embryonic pancreas and the adult islets (Persson-Sjogren et al., 2002; D.S. et al., unpublished data). Our results suggest that the VMAT2-dopamine signal plays important roles both during pancreas development and in the maintenance of β cell mass.

It was previously reported that NECA promotes β cell regeneration in a zebrafish model and that adenosine kinase inhibitors increase primary β cell proliferation (Annes et al., 2012). We found that NECA functions by antagonizing dopamine signaling to increase β cell proliferation and decrease β cell apoptosis.

The detailed mechanism of the crosstalk between ADORA2A and DRD2 signaling in β cell proliferation is not yet known. Adenosine signaling is mediated by ADORA2A, which is a Gαi-coupled receptor that increases cAMP. Dopamine signaling is mediated by a Gαs-coupled receptor DRD2, which decreases cAMP. Thus, ADORA2A and DRD2 exert opposing effects on cAMP levels, and they have been reported to be highly co-localized and form heterodimers in the striatum (Fuxe et al., 2001) and neuronal cells (Kamiya et al., 2003) where the heterodimer antagonizes homodimer formation of ADORA2A/ADORA2A or DRD2/DRD2, to modulate dopaminergic activity (Ferre et al., 1991; Hall and Strange, 1999). L-Dopa treatment, which activates dopamine signaling, was reported to disrupt heteromer formation (Bonaventura et al., 2014; Pinna et al., 2014).

Crosstalk between adenosine and dopamine signaling through other mechanisms has also been observed. ADORA2A mediates the phosphorylation of dopamine- and cAMP-regulated phosphoprotein of Mr 32,000 (DARPP-32) at Thr34 (the cAMP-dependent protein kinase site) in striatopallidal neurons, and has been reported to oppose DRD2 signaling (Shuto et al., 2006; Yabuuchi et al., 2006). Similarly, dopamine signaling has been reported to exert opposing effects on GLP-1 through phosphorylation of the serine/threonine kinase AKT, its downstream substrate GSK3β, and several other downstream signaling molecules (Ustione et al., 2013).

Our results, showing that activation of the adenosine signaling pathway by NECA together with DPD application in MIN6 cells and islet β cells further increased cell numbers compared with their single applications, thereby suggest that DRD2 and ADORA2A signal via different pathways. This notion is supported by the ability of NECA to overcome dopamine-dependent cell loss and the dopamine-dependent decrease in β cell proliferation. Our results suggest that dopamine inhibits adenosine signaling at least in part through ADORA2A-DRD2 heterodimer formation, so that ADORA2A receptor cannot activate downstream signaling events. However, it remains unknown how heterodimerization acts on cAMP levels and how it affects downstream signaling events.

In conclusion, the present study revealed the role of dopamine signaling in the control of β cell proliferation and apoptosis, and the maintenance of β cell differentiation; dopamine acts through DRD2 to decrease cAMP. Dopamine also functions through negatively regulating other signaling pathways such as the adenosine pathway. Our finding could be beneficial for the development of new targets for increasing β cell mass.

**EXPERIMENTAL PROCEDURES**

**Animals**
RIP-Cre (Postic et al., 1999) and Rosa26-EYFP (Srinivas et al., 2001) have been previously described. All animal procedures were performed in accordance with the guidelines for the care and use of animals of Kumamoto University and Tokyo Institute of Technology.

**Chemicals**
DPD and NECA were purchased from Tocris Bioscience. dBu-cAMP was purchased from BIOMOL International. Dopamine was obtained from Toronto Research Chemicals. Test compounds were dissolved in DMSO and were added to cells on day 3 and assayed on day 5, unless otherwise indicated. Final concentrations of the chemicals used were: 0.5 μM DPD, 0.25 μM NECA, 1.0 μM dBu-cAMP, 1.0 μM dopamine, and 1.0 μM SIT unless otherwise indicated.

**Islet Isolation and Screening Culture**
Mouse islets from 10-week-old C57BL/6 mice (SLC) and RIP-Cre/R26-eyFP mice were isolated as described previously (Kikawa et al., 2014). Isolated islets were handpicked and dissociated into single cells by incubation with 0.05% trypsin-EDTA (Invitrogen) for 5 min at 37°C and 5% CO2 and pipetting. The dissociated cells were plated in 96-well plates at a density of 2,000 cells per well in DMEM supplemented with 10% fetal bovine serum, 100 μM non-essential amino acids, 2 mM L-glutamine, 50 units/ml penicillin,
50 µg/ml streptomycin, and 100 µM 2-mercaptoethanol (Sumitomo Bakelite).

**EdU Incorporation**

Cells were incubated in culture medium containing 20 µM EdU for 48 hr prior to harvest (days 3–5), unless otherwise indicated, then processed using the Click-IT EdU Alexa Fluor 594 Imaging Kit (Invitrogen), and stained with DAPI and anti-insulin antibodies.

**Screening of Small Molecules and Quantitative Imaging Analysis**

Small molecules from the bioactive, pharmacologically defined Prestwick Chemical Library were screened for pro-differentiation activity. Compounds were dissolved in DMSO and added at a 1:100 dilution on day 3. Cells were assayed by immunostaining with an anti-insulin antibody on day 5. Fluorescent images were quantified by counting the number of pixels, representing the number of positive cells, using an ImageXpress micro scanning system and MetaXpress cellular image analysis software (Molecular Devices). Data are reported as the relative fold changes normalized to the DMSO-only controls. A hit compound was defined as a compound causing a 2-fold or higher increase in the number of EdU-positive insulin-positive β cells. Candidate compounds were tested for dose dependency and reproducibility.

**Immunocytochemistry**

Cells were fixed with 4% paraformaldehyde for 30 min. The following antibodies were used: guinea pig anti-insulin (A0564, Dako Denmark; 1:500), mouse anti-glucagon (G2654, Sigma-Aldrich; 1:500), rabbit anti-DRD2 receptor (251384, ABBIOTEC; 1:500), rabbit anti-GFP (598, Medical & Biological Laboratories; 1:500), rabbit anti-DRD2 receptor antibody (251384, ABBIOTEC) or mouse monoclonal [7FG-G5-A2] against ADORA2A (ab115250, Abcam). In brief, mouse islet cells were plated at 6 × 10^4 cells per well in 96-well culture plates on the day of transfection (0.3 µg of plasmid DNA). DNA was mixed with Opti-MEM medium (Life Technologies) containing Hilymax (Dojin) at a ratio of 3:1 to total DNA and then added to the cells.

**Gene Silencing**

For the Drd2 knockdown assays, cells were transfected with either Expression Arrest, non-silencing, control short hairpin RNA (shRNA) (Open Biosystems; #RHS4080) or Drd2 shRNA (Open Biosystems; #TRCN0000025738). The lentiviral vectors were constructed as previously described (Golla and Seethala, 2002), and MIN6 cells were infected with viral supernatants. After a 24-hr incubation, the virus-containing medium was replaced with fresh ESC maintenance medium. After another 24 hr incubation, infected cells were selected by the addition of 1.5 µg/ml puromycin. The surviving cells were harvested, and clones were selected to establish knockdown and control cell lines.

**cAMP Content Measurement**

cAMP levels were calculated using the cAMP-Glo Assay (Promega) following the manufacturer’s protocol. In brief, MIN6 cells were grown in 96-well plates and lysed with the buffer provided in the kit. Intracellular cAMP levels were detected using the detection solution provided in the kit. Luminescence was measured using a GloMax 96 Microplate Luminometer (Promega). A standard curve was generated in parallel for each experiment using serial dilutions of the cAMP standard provided with the kit.

**Co-immunoprecipitation and Western Blot Analysis**

Co-immunoprecipitation was performed using rabbit anti-DRD2 receptor antibody (251384, ABBIOTEC) or mouse monoclonal [7FG-G5-A2] against ADORA2A (ab115250, Abcam). In brief, mouse islet cells were lysed with RIPA buffer (50 mM Tris [pH 7.4], 150 mM NaCl, 1% NP-40, 0.1% SDS, 1.5 mM MgCl₂) and the cellular extracts were incubated for 16 hr with the antibody coupled to Protein A/G PLUS-Agarose beads (Santa Cruz Biotechnology, #sc-2003) at 4°C under rotation. Immunoprecipitates were spun down and washed six times in RIPA buffer. Co-immunoprecipitates were dissolved with 2x Laemmli buffer and boiled for 5 min for SDS-PAGE.

SDS-PAGE was carried out using an 8% acrylamide gel. Western blot analysis of DRD2 or ADORA2A after co-immunoprecipitation was carried out on polyvinylidene fluoride membranes using primary antibody and Immuno-Aptamer rabbit IgG (Nippon Gene, 310-07,291). After washing with TBST (TBS containing 0.05% Tween 20), the membrane was incubated with TBST containing streptavidin-horseradish peroxidase conjugate (1:10,000; Perkin Elmer, #NEL75001EA) antibody. Finally, the membrane was reacted.

**Real-Time PCR Analysis**

RNA was extracted from cells using the RNeasy mini-kit (Qiagen) and treated with DNase I (Qiagen). cDNA was synthesized from 1 µg of total RNA using Revertra Ace qPCR RT Master Mix (Toyobo).

For the real-time PCR analysis, mRNA expression was quantified by amplification in an ABI 7500 thermal cycler (Applied Biosystems) with SYBR Green. Gene expression of target genes was normalized to that of β-actin. The PCR conditions were as follows: denaturation at 95°C for 15 s and annealing and extension at 60°C for 60 s, for up to 40 cycles. Each measurement was normalized to β-actin (mouse) or GAPDH (human) by subtracting the average β-actin or GAPDH expression level. Target mRNA levels were expressed as a.u. and were determined using the standard curve method. All primers used for real-time PCR are listed in Table S1.
with ECL Prime reagents (GE Healthcare) and scanned using a Fusion Solo (Vilber-Lourmat) imaging system.

Duolink In Situ Proximity Ligation Assay
Direct protein-protein interactions were investigated by means of a proximity ligation assay (PLA) (Soderberg et al., 2006) using Duolink In Situ Red Starter Kit Mouse/Rabbit (Sigma). Dispersed islet cells were washed with PBS and then either immediately fixed, or cultured for 3 days and treated with chemicals for 6 hr then fixed on the culture dish at room temperature for 30 min in 4% paraformaldehyde, for further use in Duolink PLA. Cells were further rinsed for 10 min with PBS containing 1% Triton X-100 (Sigma) and then washed for 10 min three times with 0.05% Tween 20 in PBS to allow permeabilization. Duolink II blocking solution was then added into wells, followed by incubation for 1 hr at room temperature. The blocking solution was then tapped off and cells were incubated for 1 hr at 37°C with primary antibodies. Primary antibodies used were: rabbit anti-DRD2 receptor antibody (1:500; ABBIOTEC, #251384) or mouse monoclonal (7FG-G5-A2) to ADORA2A (1:500; Abcam, #ab79714). Duolink anti-rabbit PLUS and anti-mouse MINUS secondary antibodies and red detection reagents were used and antibody incubation, ligation, amplification, and washing steps were performed according to the supplier’s manual. Cells were then immunocytochemically stained with anti-insulin antibody and DAPI. The average intensity of PLA signals in insulin-positive cell area was calculated by MetaMorph software (Molecular Devices).

Human Islets
Non-diabetic human islets were obtained from Prodo Laboratories, and cultured in Prodo Islet Medium (Prodo Laboratories). Donor information is as follows. Age, 56; gender, female; ethnicity, African American; body mass index, 33.4; diabetes, no history; and hemoglobin A1c, 5.2%. Chemicals were added on days 1–3 after isolation with three to six biological replicates, unless otherwise indicated.

Statistics
Data are expressed as the mean ± SD. Differences between groups were analyzed by Student’s t test. A p value of less than 0.05 was considered statistically significant. Data were confirmed in three to four independent experiments for reproducibility, each experiment with three to six biological replicates, unless otherwise indicated.

SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and one table and can be found with this article online at http://dx.doi.org/10.1016/j.stemcr.2016.05.015.

AUTHOR CONTRIBUTIONS
D.S., N.S., and S.K. conceived the project and designed the study; D.S., S.C., and M.K. performed most experiments; M.U. provided the chemical library; D.S., N.S., M.U., K.K., and S.K. contributed to data analysis and interpretation; D.S. and S.K. wrote the paper; all the authors approved the final version of the manuscript.

ACKNOWLEDGMENTS
We thank Mr. Yuki Sonoda and Ms. Misako Katabuchi for technical assistance and helpful discussions, and Dr. Junji Hirota and the members of the Center for Biological Resources and Informatics at Tokyo Institute of Technology, and the members in the Center for Animal Resources and Development at Kumamoto University for their technical assistance. This work was supported by grants (26253059 and 26670384 to S.K., 26461638 to N.S., and 26461036 to D.S.) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) Japan. This work was also supported in part by the Takeda Science Foundation, Japanese Insulin Dependent Diabetes Mellitus (IDDM) Network Foundation, and the Program for Leading Graduate Schools ‘HIGO’ to Kumamoto University from MEXT. S.K. is a member of the HIGO Program, MEXT, Japan.

Received: August 18, 2015
Revised: May 27, 2016
Accepted: May 31, 2016
Published: June 30, 2016

REFERENCES


by targeted insertion of EYFP and ECFP into the ROSA26 locus.

BMC Dev. Biol. 1, 4.


